+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years +
All Genders
ID07804056

Randomized Study Evaluating Alpha1H Before Surgery Compared to Standard Care in Adults with Low- to Intermediate-Risk Non-Muscle-Invasive Bladder Cancer

Led by Hamlet Pharma AB · Updated on 2026-09-21

194

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the drug Alpha1H to treat adults with low- to intermediate-risk non-muscle-invasive bladder cancer. This clinical trial aims to determine if giving Alpha1H before surgery can reduce the chance of cancer returning or worsening compared to standard care alone. The study also assesses the safety and tolerability of Alpha1H by comparing outcomes between participants receiving the drug and those receiving standard care. Participants are randomly assigned to one of two groups. One group receives six doses of Alpha1H directly into the bladder over about one month before undergoing surgery to remove tumor tissue. During each treatment, they hold the drug in their bladder for up to two hours. The other group receives standard care, which includes surgery followed by a single dose of standard chemotherapy in the bladder. Tumor tissue removed during surgery is analyzed, and participants are followed for up to three years. Throughout the study, participants attend regular clinic visits for bladder exams, urine tests, and questionnaires about quality of life. Researchers monitor cancer-free survival, tumor response, gene expression, immune markers, adverse events, and overall survival. The main outcome is event-free survival measured at multiple time points up to three years after randomization. This allows careful evaluation of treatment effects and safety over time.

CONDITIONS

Brief Title

A Study to Investigate the Efficacy and Safety of Alpha1H as a Neoadjuvant Therapy in Participants With Low- to Intermediate-Risk/Low-Grade Papillary Non-Muscle Invasive Bladder Cancer

Research Team

C

Catharina Svanborg, MD, PhD.

P

Petr Bouska

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here